Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- cardiac
- Therapeutic
- Drug Discovery
- Pharmaceuticals
- Medical
- Device
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 5786
Thrombosis is the formation of a blood clot (thrombus) inside a blood vessel, obstructing the flow of blood through the circulatory system. When a blood vessel is injured, the body uses platelets and fibrin to form a blood clot, because the first step in repairing it (hemostasis) is to prevent loss of blood. Thrombosis is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system.
Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. It prevents blood from flowing normally through the circulatory system.
IPSCIO Record ID: 368507
U.S. Patent 6,525,078 B1 dated February 24, 2003 entitled “Compound for the Treatment of Athreosclerotic-Thrombotic Pathological Conditions.
Atherosclerosis is thickening or hardening of the arteries caused by a buildup of plaque in the inner lining of an artery.
Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. It prevents blood from flowing normally through the circulatory system. Blood clotting, also known as coagulation, is the body's first line of defense against bleeding.
Coronary disease (MCD) is the narrowing of the small blood vessels that branch off the coronary arteries and send oxygen-rich blood to the heart muscle. This decreases the amount of blood that goes to the heart muscle, which leads to chest pain (angina).
IPSCIO Record ID: 372642
– U.S. Utility Application No.11/700,987, Filed 2/1/2007, “A METHOD AND APPARATUS FOR INCREASING BLOOD FLOW THROUGH AN OBSTRUCTED BLOOD VESSELâ€, Henry Woo, MD, David Fiorella, MD, PhD. Publication Number US 20070208361 A1.
– U.S. Application No.60/764,206, Filed 2/1/2006, “A METHOD AND APPARATUS FOR INCREASING BLOOD FLOW THROUGH AN OBSTRUCTED BLOOD VESSELâ€, Henry Woo, MD, David Fiorella, MD, PhD. Expired.
-U.S. Application No.60/793,588, Filed 4/20/2006, “A METHOD AND APPARATUS FOR INCREASING BLOOD FLOW THROUGH AN OBSTRUCTED BLOOD VESSELâ€, Henry Woo, MD, David Fiorella, MD, PhD. Expired.
Ischemic stroke occurs when a blood clot blocks or narrows an artery leading to the brain. A blood clot often forms in arteries damaged by the buildup of plaques (atherosclerosis). It can occur in the carotid artery of the neck as well as other arteries. This is the most common type of stroke.
IPSCIO Record ID: 314347
Compound shall mean the Thrombin Inhibitor compounds with potential therapeutic value.
Intellectual Property Rights means any and all intellectual property rights, including without limitation patents, patent applications, any copyrights and registrations and applications for registration thereof, computer software, programs, data and documentation, technology, trade secrets and confidential business information, whether patentable or non-patentable and whether or not reduced to practice, know-how, designs, prototypes, laboratory protocols, enhancements, improvements, works-in-progress, research and development information, and other proprietary rights relating to any of the foregoing (including without limitation remedies against infringements thereof and rights of protection of an interest therein under the laws of all jurisdictions).
Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. It prevents blood from flowing normally through the circulatory system.
IPSCIO Record ID: 243472
Product shall mean any pharmaceutical composition containing Compound as an active ingredient, in any formulation, delivery system or package configuration.
Compound shall mean the chemical compound, having dual antagonistic activity against both integrin alpha Vbeta3 and GPilbllla receptors which activity substantially contributes to the therapeutic efficacy for its intended use, which is the compound defined as (2S)-benzenesulfonylamino-3-[3-methoxy-4-{4-(1,4,5,6-tetrahydropyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionic acid and designated by the Licensor internal code name of CP4715.
MN-447 and MN-462 are antithrombic (anti-clotting) agents that represent novel approaches to blood clot formation and lysis, respectively, and are expected to treat a variety of thrombotic disorders.
MN-447 is a novel cardioprotective, anti-platelet agent that acts as a potent dual antagonist of glycoprotein (GP) IIbIIIa and integrin alpha-v-beta-3 receptors that play key roles in blood clot formation and various cell behaviors and functions such as leukocyte adhesion. MN-447 acts downstream by inhibiting the final common pathway of platelet aggregation — the cross-linking of platelets via fibrinogen bridges to GP IIbIIIa receptors. Inhibition of integrin alpha-v-beta-3 receptors has been linked to an inhibition of leukocyte adhesion to endothelium (the layer of cells lining blood vessels), reduction of hyperplasia (abnormal cellular proliferation) and lumen stenosis (blood vessel constriction) in response to vascular injury. In animal models of myocardial infarction and unstable angina, the dual inhibitory activity of MN-447 produced superior cardioprotective efficacy, such as reduction in infarct size after reperfusion (restoration of blood flow), compared to inhibition of the GP IIbIIIa receptor alone and showed a low risk of bleeding.
MN-462 is a selective inhibitor of a key enzyme in the intrinsic antifibrinolytic mechanism, plasma carboxypeptidase B (CPB; also called activated thrombin-activatable fibrinolysis inhibitor (TAFIa)), which inhibits physiological fibrinolysis (the lysis or dissolving of blood clots). By enhancing intrinsic fibrinolysis through plasma CPB inhibition, MN-462 has the potential to both reduce and prevent thrombus or blood clot formation as well as to dissolve formed thrombus, and consequently, represents a novel approach to treating various thrombotic disorders. In preclinical studies, MN-462 has demonstrated significant fibrinolytic-enhancing and anti-thrombotic activities as monotherapy in several thrombosis models, as well as activities when used as an adjunct to fibrinolytics such as tissue plasminogen activator (t-PA). The effect of MN-462 in enhancing the intrinsic fibrinolytic process has also been observed to result in a low risk of bleeding.
IPSCIO Record ID: 328338
For Other Indications for Licensed Compounds, Licensor grants a right of first refusal to obtain licenses to use Licensed Compounds for other applications or indications outside the Field.
For Rights to Related Compounds. Licensor grants the right to include within the license rights granted under the License specific Related Compounds.
The Parties are to develop and commercialize LR-3280 and certain related oligonucleotide compounds in Japan and certain other countries in Asia for the prevention or treatment of restenosis in any blood vessel following an angioplasty or similar procedure, and Licensor will supply Licensee quantities of product containing such compounds for clinical use and commercial sale.
The patents subject matter includes but is not limited to
– Method of inhibition smooth muscle cell proliferation by treating with c-myc antisense;
– Method of treating restenosis by administrating c-myr antisense;
– Method of Inhibiting collagen synthesis by treating with c-myr antisense;
– Method of treating vascular grafts to reduce stenosis by applying c-myr antisense to graft; and,
– Pharmaceutical compositions for the above methods.
Licensed Compounds means the oligonucleotide compound identified by Licensor as LR-3280, and any other phosphorothioated oligonucleotidc compounds that now or hereafter are owned or Controlled by Licensor or its Affiliates and that specifically target the mRNA transcribed from the c-myc gene, or contain four deoxyguanosine nucleotides in a row and are developed by Licensor for use in the Field.
Clinical Trial Product means a product, appropriate for use in clinical trials, containing a Licensed Compound or placebo, as applicable, in the formulation as determined by Licensee.
Restenosis is the recurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually pertains to an artery or other large blood vessel that has become narrowed, received treatment to clear the blockage and subsequently become renarrowed.
